Risk factor
Sufficiently resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
LanZhou Foci Pharmaceutical Co.,Ltd. is a prominent pharmaceutical entity based in China, primarily focused on the manufacturing and distribution of traditional Chinese medicines. Its diverse product line, offered under the "Min Shan" and "Foci" brand names, encompasses a variety of formats, including pills, tablets, capsules, and granules. Beyond its production activities, the company actively pursues research and development initiatives aimed at pioneering novel herbal remedies. Its global footprint extends to approximately 27 countries, with key export markets including the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, and Hong Kong. Established in 1929, the firm's headquarters are located in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of the Lanzhou Foci Pharmaceutical Factory.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB